Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Boehringer Ingelheim
Merck
Express Scripts
McKesson

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EPIRUBICIN HYDROCHLORIDE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Epirubicin Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002529 Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer Completed International Breast Cancer Study Group Phase 3 1993-05-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy may fight breast cancer by blocking the uptake of estrogen. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with hormone therapy may kill more tumor cells. It is not yet known which treatment regimen is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of hormone therapy during or after combination chemotherapy or hormone therapy alone in treating perimenopausal or postmenopausal women who have stage II or stage IIIA breast cancer.
NCT00002542 Tamoxifen in Treating Women With High-Risk Breast Cancer Completed NCIC Clinical Trials Group Phase 3 1993-07-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase III trial to study the effectiveness of tamoxifen following surgery and chemotherapy in treating women who have stage I breast cancer at high risk of recurrence or stage II or stage III breast cancer.
NCT00002544 Mitoxantrone With or Without Docetaxel in Treating Women With Metastatic Breast Cancer Completed Arbeitsgemeinschaft fur Internistische Onkologie Phase 3 1993-05-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if mitoxantrone is more effective with or without docetaxel. PURPOSE: Randomized phase III trial to compare the effectiveness of mitoxantrone with or without docetaxel in treating women who have metastatic breast cancer with a poor prognosis.
NCT00002615 Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer Completed Medical Research Council Phase 3 1994-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not known whether receiving chemotherapy before surgery may be more effective than surgery alone in treating patients with stomach cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of surgery plus combination chemotherapy with surgery alone in treating patients with stomach cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Epirubicin Hydrochloride

Condition Name

Condition Name for Epirubicin Hydrochloride
Intervention Trials
Breast Cancer 156
Gastric Cancer 33
Breast Neoplasms 19
Esophageal Cancer 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Epirubicin Hydrochloride
Intervention Trials
Breast Neoplasms 230
Stomach Neoplasms 46
Adenocarcinoma 30
Esophageal Neoplasms 29
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Epirubicin Hydrochloride

Trials by Country

Trials by Country for Epirubicin Hydrochloride
Location Trials
United States 522
Italy 139
China 110
Germany 79
Spain 76
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Epirubicin Hydrochloride
Location Trials
Texas 26
New York 24
California 20
Florida 20
Pennsylvania 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Epirubicin Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Epirubicin Hydrochloride
Clinical Trial Phase Trials
Phase 4 14
Phase 3 125
Phase 2/Phase 3 16
[disabled in preview] 166
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Epirubicin Hydrochloride
Clinical Trial Phase Trials
Completed 152
Recruiting 83
Unknown status 42
[disabled in preview] 40
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Epirubicin Hydrochloride

Sponsor Name

Sponsor Name for Epirubicin Hydrochloride
Sponsor Trials
National Cancer Institute (NCI) 25
German Breast Group 16
Hoffmann-La Roche 15
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Epirubicin Hydrochloride
Sponsor Trials
Other 569
Industry 170
NIH 26
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Boehringer Ingelheim
Merck
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.